Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer

被引：1
|
作者：
Atkins, CD
机构：
来源：
JOURNAL OF THE NATIONAL CANCER INSTITUTE | 1998年 / 90卷 / 06期
关键词：
D O I：
10.1093/jnci/90.6.468
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：468 / 468
页数：1
相关论文
共 50 条
  • [31] Adjuvant Chemotherapy Decisions in Clinical Practice for Early-Stage Node-Negative, Estrogen Receptor-Positive, HER2-Negative Breast Cancer: Challenges and Considerations
    Nagaraj, Gayathri
    Ma, Cynthia X.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (03): : 246 - 251
  • [32] PROSPECTIVE TRANSGEICAM STUDY OF ONCOTYPE DX® IN CLINICAL DECISION MAKING IN ESTROGEN RECEPTOR-POSITIVE NODE-NEGATIVE BREAST CANCER WOMEN
    Albanell, J.
    Colomer, R.
    Ruiz-Borrego, M.
    Saenz, J. A. Garcia
    Alba, E.
    Martin, M.
    Palacios, J.
    Faull, I.
    Corominas, J. M.
    Lluch, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 81 - 81
  • [33] Nodal staging affects adjuvant treatment choices in elderly patients with clinically node-negative, estrogen receptor-positive breast cancer
    Laws, A.
    Cheifetz, R.
    Warburton, R.
    McGahan, C. E.
    Pao, J. S.
    Kuusk, U.
    Dingee, C.
    Quan, M. L.
    McKevitt, E.
    CURRENT ONCOLOGY, 2020, 27 (05) : 250 - 256
  • [34] A new marker of tamoxifen resistance of estrogen receptor-positive breast cancer
    Bogush, E. A.
    Ravcheeva, A. B.
    Bogush, T. A.
    Zabotina, T. N.
    Kadagidze, Z. G.
    Davydov, M. I.
    DOKLADY BIOCHEMISTRY AND BIOPHYSICS, 2007, 413 (01) : 83 - 87
  • [35] Safely Omitting Sentinel Lymph Node Biopsy in Women 70 Years Old with Early Stage, Clinically Node-Negative, Estrogen Receptor-Positive, HER2-negative Breast Cancer
    Seo, Dianne
    Sizer, Lina
    Roudakova, Kseniya
    Kjelstrom, Stephanie
    Carruthers, Catherine C.
    Carter, William B.
    Lamb, Elena
    Frazier, Thomas G.
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (SUPPL 2) : 419 - 419
  • [36] A new marker of tamoxifen resistance of estrogen receptor-positive breast cancer
    E. A. Bogush
    A. B. Ravcheeva
    T. A. Bogush
    T. N. Zabotina
    Z. G. Kadagidze
    M. I. Davydov
    Doklady Biochemistry and Biophysics, 2007, 413 : 83 - 87
  • [37] Prognostic implications of HER-2 status in steroid receptor-positive, lymph node-negative breast carcinoma
    Peiro, Gloria
    Adrover, Encarna
    Aranda, Francisco I.
    Peiro, Francisca M.
    Niveiro, Maria
    Sanchez-Paya, Jose
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2007, 127 (05) : 780 - 786
  • [38] The use of Ki67 to predict benefit from adjuvant tamoxifen in node-negative, estrogen receptor-positive patients.
    Yerushalmi, R.
    Woods, R.
    Gelmon, K. A.
    Spears, C.
    Ravdin, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [39] The Impact of the Oncotype DX Breast Cancer Assay on Treatment Decisions for Women With Estrogen Receptor-Positive, Node-Negative Breast Carcinoma in Hong Kong
    Leung, Roland C. Y.
    Yau, Thomas C. C.
    Chan, Miranda C. M.
    Chan, Sharon W. W.
    Chan, Terence W. C.
    Tsang, Yvonne Y. Y.
    Wong, Ting Ting
    Chao, Calvin
    Yoshizawa, Carl
    Soong, Inda S.
    Kwan, Wing-Hong
    Kwok, Carol C. H.
    Suen, Joyce S. J.
    Ngan, Roger K. C.
    Cheung, Polly S. Y.
    CLINICAL BREAST CANCER, 2016, 16 (05) : 372 - 378
  • [40] MicroRNAs in estrogen receptor-positive and -negative breast cancer cells
    Miyamoto, Kazuaki
    Miyamoto, Haruko
    CANCER RESEARCH, 2009, 69
12345